🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Suzanne Nielsen

ORCID: 0000-0001-5341-1055

Also affiliated with Monash University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.815Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia

International Journal of Epidemiology(2020)10.1093/ije/dyaa125

Top 25%

0.815DataRank

Top 25%20 citations

N. R. Jones, David A. Fiellin, Suzanne Nielsen, Matthew Hickman, Timothy Dobbins +4 more

Papers

Driven by 12 papers — median percentile 75. Top paper: “Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence”.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

International Journal of Drug Policy(2021)10.1016/j.drugpo.2021.103492

N/A

2.1DataRank · unranked

52 citations

Jeyran Shahbazi, Marianne Byrne, Jason Grebely, Nicholas Lintzeris, Mark S. Chambers +13 more

Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia

International Journal of Epidemiology(2020)10.1093/ije/dyaa125

Top 25%

0.815DataRank

Top 25%20 citations

N. R. Jones, David A. Fiellin, Suzanne Nielsen, Matthew Hickman, Timothy Dobbins +4 more

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

International Journal of Drug Policy(2024)10.1016/j.drugpo.2024.104390

N/A

0.730DataRank · unranked

21 citations

Jeyran Shahbazi, Mark S. Chambers, Marianne Byrne, Jaleh Gholami, Emma Zahra +14 more

Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence

International Journal of Drug Policy(2024)10.1016/j.drugpo.2024.104359

N/A

0.616DataRank · unranked

15 citations

Sandra Gendera, Carla Treloar, Tim Rhodes, Jeyran Shahbazi, Marianne Byrne +4 more

Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis

Drug and Alcohol Dependence(2020)10.1016/j.drugalcdep.2020.108343

N/A

0.330DataRank · unranked

8 citations

N. R. Jones, Matthew Hickman, Sarah Larney, Nadine Ezard, Suzanne Nielsen +2 more

Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17

Addiction(2023)10.1111/add.16178

N/A

0DataRank · unranked

17 citations

N. R. Jones, Matthew Hickman, Suzanne Nielsen, Robert Ali, Louisa Degenhardt +1 more

Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia

Journal of Psychiatric Research(2020)10.1016/j.jpsychires.2020.08.013

N/A

0DataRank · unranked

48 citations

N. R. Jones, Matthew Hickman, Suzanne Nielsen, Louisa Degenhardt, Dan Lewer

Identifying key risk factors for intentional self‐harm, including suicide, among a cohort of people prescribed opioid agonist treatment: A predictive modelling study

Addiction(2025)10.1111/add.70095

N/A

0DataRank · unranked

2 citations

Matthew Hickman, Chrianna Bharat, Suzanne Nielsen, Sarah Larney, Nimnaz Fathima Ghouse +3 more

Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001–2018: Implications for treatment systems and potential impact on client outcomes

Drug and Alcohol Dependence(2020)10.1016/j.drugalcdep.2020.108464

N/A

0DataRank · unranked

27 citations

Suzanne Nielsen, Michael Farrell, Robert Ali, Anthony J. Gill, Sarah Larney +2 more

Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001–2018: Findings from the OATS retrospective cohort study

Drug and Alcohol Dependence(2020)10.1016/j.drugalcdep.2020.108354

N/A

0DataRank · unranked

11 citations

Matthew Hickman, Sarah Larney, Suzanne Nielsen, Robert Ali, Thomas J. Murphy +4 more

Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.3059

N/A

0DataRank · unranked

9 citations

Phillip Hungerford, Suzanne Nielsen, Raimondo Bruno, Briony Larance, Philip Clare +8 more

Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross‐sectional survey of Australian treatment clients

Drug and Alcohol Review(2022)10.1111/dar.13437

N/A

0DataRank · unranked

12 citations

Rory Chen, Suzanne Nielsen, Anh Tran, Thomas Santo, Louisa Degenhardt +5 more